Prostate Cancer Clinical Trial
Official title:
Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making
The purpose of this study is to test different methods for communicating information about prostate cancer treatment to men. The investigators are studying how best to present information so men can make informed decisions about what prostate cancer treatment to undergo.
Background/Rationale: Prostate cancer is the second leading cause of cancer related death
among men in the United States, and accounts for 29% of all cancers diagnosed in men.
Furthermore, approximately one in six men will be diagnosed with prostate cancer in their
lifetime. Thus, 17% of male Veterans will be asked to make a decision about the treatment of
their prostate cancer. The burden of this disease is further magnified when one considers
that most patients will live for years following their diagnosis and with any adverse
effects of therapy. Given that there have been no clinical trials showing that any prostate
cancer treatment produces an increased likelihood of survival; men are asked to actively
participate in treatment decisions. Previous research has revealed that men are often
uninformed about their prostate cancer, particularly African American men and men with lower
educational attainment. Thus, it is critical to develop and test decision aids that can help
all men (especially men with low literacy skills) make an informed decision.
Objective(s): The goal of the study is to compare the impact of a plain language decision
aid (DA) to a conventional DA on prostate cancer patients' decision making experience and
communication with their physician.
Methods: This study is a randomized controlled trial. Men undergoing a prostate biopsy will
be recruited at the time of biopsy and complete a baseline interview (at pre-biopsy or
biopsy appointment). Those patients diagnosed with localized prostate cancer will complete
two additional interviews: at physician visit (diagnosis), and 7-10 days following physician
visit (phone survey). The treatment discussion between patients and their physician will be
audio recorded.
Major characteristics: All men, without a prior history of prostate cancer, undergoing a
prostate biopsy will be screened for eligibility and enrolled by the study coordinator.
Additional inclusion criteria include ability to speak English, provide informed consent,
and have a PSA < 20. Physicians can refuse to allow a patient participate in the study at
the time of biopsy. Men will be recruited from 4 VA hospitals (Ann Arbor, Durham,
Pittsburgh, and San Francisco) and randomized to receive one of two decision aid booklets
(plain language vs. conventional).
Major variables and source(s) of data: All survey data will be collected from either
face-to-face or phone interviews. The surveys include measures of literacy, numeracy,
anxiety, preference for shared decision making, knowledge, treatment preferences, risk
perceptions, perception of patient-physician communication, and confidence and satisfaction
with the decision making process. All survey questions were read aloud and responses
recorded.
Status: Recruitment began in September 2008 and concluded in May of 2012.
1552 men were approached to participate in the study with 1028 agreeing. 1023 completed the
Time 1 interview. Of the 334 subjects eligible to continue with study activities, 285
subjects completed the Time 2 interview (biopsy results visit), and 244 completed the Time 3
phone interview.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |